Cargando…

Development of Lutein-Containing Eye Drops for the Treatment of Dry Eye Syndrome

Dry eye syndrome (DES) is a common ophthalmological disease that decreases tear secretion and causes dryness, photophobia, pain, severe corneal rupture, and even blindness. Ocular and lacrimal gland inflammation is one of the pathological mechanisms underlying DES. Therefore, effective suppression o...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yi-Zhou, Chen, Zhi-Yu, Tang, Yu-Jun, Tsai, Cheng-Han, Chuang, Yu-Lun, Hsieh, Erh-Hsuan, Tucker, Lachlan, Lin, I-Chan, Tseng, Ching-Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8621052/
https://www.ncbi.nlm.nih.gov/pubmed/34834216
http://dx.doi.org/10.3390/pharmaceutics13111801
_version_ 1784605364634779648
author Chen, Yi-Zhou
Chen, Zhi-Yu
Tang, Yu-Jun
Tsai, Cheng-Han
Chuang, Yu-Lun
Hsieh, Erh-Hsuan
Tucker, Lachlan
Lin, I-Chan
Tseng, Ching-Li
author_facet Chen, Yi-Zhou
Chen, Zhi-Yu
Tang, Yu-Jun
Tsai, Cheng-Han
Chuang, Yu-Lun
Hsieh, Erh-Hsuan
Tucker, Lachlan
Lin, I-Chan
Tseng, Ching-Li
author_sort Chen, Yi-Zhou
collection PubMed
description Dry eye syndrome (DES) is a common ophthalmological disease that decreases tear secretion and causes dryness, photophobia, pain, severe corneal rupture, and even blindness. Ocular and lacrimal gland inflammation is one of the pathological mechanisms underlying DES. Therefore, effective suppression of inflammation is a crucial strategy for the treatment of DES. Lutein, commonly found in healthy foods, has anti-inflammatory effects in corneal or retina-related cells and may be a potential therapy for DES. The addition of lutein to artificial tears (AT) as an eye-drop formulation for DES treatment in a mouse model was studied in the present work. Polyvinyl alcohol (PVA) was used as a thickener to increase the viscosity of eye drops to prolong drug retention on the ocular surface. A WST-8 assay in human corneal epithelial cells (HCE-2) showed that a concentration of <5 μM lutein (L5) and <1% PVA (P1) maintained the cell viability at 80%. A real-time PCR showed that the inflamed human corneal epithelial cells (HCECs) cocultured with L5P1 had downregulated expression of inflammatory genes such as IL-1β, IL-6, and TNF-α. In a benzalkonium chloride- (BAC) induced DES mouse model, AT/L5P1 could repair damaged corneas, elevate tear secretion, increase the number of goblet cells, and inhibit the production of inflammatory cytokines, such as IL-1β, IL-6, and TNF-α, in the cornea. In conclusion, we demonstrate that lutein/PVA as eye drops could prolong the drug ocular retention time and effectively to decrease inflammation in DES mice. Therefore, lutein, obtained from eye drops, has a potential therapeutic role for DES.
format Online
Article
Text
id pubmed-8621052
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86210522021-11-27 Development of Lutein-Containing Eye Drops for the Treatment of Dry Eye Syndrome Chen, Yi-Zhou Chen, Zhi-Yu Tang, Yu-Jun Tsai, Cheng-Han Chuang, Yu-Lun Hsieh, Erh-Hsuan Tucker, Lachlan Lin, I-Chan Tseng, Ching-Li Pharmaceutics Article Dry eye syndrome (DES) is a common ophthalmological disease that decreases tear secretion and causes dryness, photophobia, pain, severe corneal rupture, and even blindness. Ocular and lacrimal gland inflammation is one of the pathological mechanisms underlying DES. Therefore, effective suppression of inflammation is a crucial strategy for the treatment of DES. Lutein, commonly found in healthy foods, has anti-inflammatory effects in corneal or retina-related cells and may be a potential therapy for DES. The addition of lutein to artificial tears (AT) as an eye-drop formulation for DES treatment in a mouse model was studied in the present work. Polyvinyl alcohol (PVA) was used as a thickener to increase the viscosity of eye drops to prolong drug retention on the ocular surface. A WST-8 assay in human corneal epithelial cells (HCE-2) showed that a concentration of <5 μM lutein (L5) and <1% PVA (P1) maintained the cell viability at 80%. A real-time PCR showed that the inflamed human corneal epithelial cells (HCECs) cocultured with L5P1 had downregulated expression of inflammatory genes such as IL-1β, IL-6, and TNF-α. In a benzalkonium chloride- (BAC) induced DES mouse model, AT/L5P1 could repair damaged corneas, elevate tear secretion, increase the number of goblet cells, and inhibit the production of inflammatory cytokines, such as IL-1β, IL-6, and TNF-α, in the cornea. In conclusion, we demonstrate that lutein/PVA as eye drops could prolong the drug ocular retention time and effectively to decrease inflammation in DES mice. Therefore, lutein, obtained from eye drops, has a potential therapeutic role for DES. MDPI 2021-10-27 /pmc/articles/PMC8621052/ /pubmed/34834216 http://dx.doi.org/10.3390/pharmaceutics13111801 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chen, Yi-Zhou
Chen, Zhi-Yu
Tang, Yu-Jun
Tsai, Cheng-Han
Chuang, Yu-Lun
Hsieh, Erh-Hsuan
Tucker, Lachlan
Lin, I-Chan
Tseng, Ching-Li
Development of Lutein-Containing Eye Drops for the Treatment of Dry Eye Syndrome
title Development of Lutein-Containing Eye Drops for the Treatment of Dry Eye Syndrome
title_full Development of Lutein-Containing Eye Drops for the Treatment of Dry Eye Syndrome
title_fullStr Development of Lutein-Containing Eye Drops for the Treatment of Dry Eye Syndrome
title_full_unstemmed Development of Lutein-Containing Eye Drops for the Treatment of Dry Eye Syndrome
title_short Development of Lutein-Containing Eye Drops for the Treatment of Dry Eye Syndrome
title_sort development of lutein-containing eye drops for the treatment of dry eye syndrome
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8621052/
https://www.ncbi.nlm.nih.gov/pubmed/34834216
http://dx.doi.org/10.3390/pharmaceutics13111801
work_keys_str_mv AT chenyizhou developmentofluteincontainingeyedropsforthetreatmentofdryeyesyndrome
AT chenzhiyu developmentofluteincontainingeyedropsforthetreatmentofdryeyesyndrome
AT tangyujun developmentofluteincontainingeyedropsforthetreatmentofdryeyesyndrome
AT tsaichenghan developmentofluteincontainingeyedropsforthetreatmentofdryeyesyndrome
AT chuangyulun developmentofluteincontainingeyedropsforthetreatmentofdryeyesyndrome
AT hsieherhhsuan developmentofluteincontainingeyedropsforthetreatmentofdryeyesyndrome
AT tuckerlachlan developmentofluteincontainingeyedropsforthetreatmentofdryeyesyndrome
AT linichan developmentofluteincontainingeyedropsforthetreatmentofdryeyesyndrome
AT tsengchingli developmentofluteincontainingeyedropsforthetreatmentofdryeyesyndrome